Bevacizumab and Carboplatin for Patients With Ovarian Cancer
This is a phase II trial to investigate the effect of bevacizumab and carboplatin in patients with platin resistant ovarian cancer.
Ovarian Cancer
DRUG: Bevacizumab|DRUG: Carboplatin
Progression free survival, From date of first treatment until date of verified progression or death. 12 months of follow-up
Overall survival, From date of first treatment until death. Up to 12 months|Response rate, Every 9 weeks until progression or death. Up to 12 months|Response duration, From date of first documented response until date of progression. Up to 12 months.
This is a phase II trial to investigate the effect of bevacizumab and carboplatin in patients with platin resistant ovarian cancer.